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Molecular Epidemiology of
Pneumocystis carinii Pneumonia
Pneumocystis carinii pneumonia (PCP) was
first recognized as a distinct clinical entity in
orphanages in Europe during World War II (1).
Todayitisthemostfrequentseriousopportunistic
infection in AIDS patients. Despite advances in
research, numerous questions remain regarding
the basic biology and epidemiology of P. carinii.
Transmission and Patient Care
Although reactivation of latent infections has
long been considered the primary explanation for
PCP in immunosuppressed patients, over the
years a steady flow of reports has described clus-
ters of PCP cases (2). In addition, recent studies
havesuggestedthatthedurationoflatencyisvery
limited, i.e., usually less than 1 year (3,4). Still
other studies have demonstrated genetic vari-
ation in PCR-amplified P. carinii DNA from the
lungs of patients during subsequentPCP episodes
(5). Together, these observations provide strong
circumstantial evidence of person-to-person
transmission of P. carinii. Consequently, estab-
lishing the role that person-to-person transmis-
sion plays in the epidemiology of PCP is urgent.
Another importantarea of PCP epidemiology is
determining the predisposing factors for disease.
Themostfrequentlydiscussedpredictorofdisease
is CD4+ cell count,specifically as it relates to care
and management of AIDS patients (6);however,it
has long been known that malnutrition can be an
important contributor (7). The degree to which
other factors such as viral infections or pneumoni-
tis of other causes, may come into play, is yet to be
shown.
Much can also be learned regarding the
epidemiology of PCP in HIV-infected infants. Re-
cent studies report that primary infections in
these infants often develop when the child is 3 to
6 months old (8,9).The source of these patients’
P.carinii infections (i.e.,the hospital setting,their
mothers, other children, or an environmental
source) is not known.
Clinicians working with AIDS patients need
a sensitive, reliable, and noninvasive tool for
early detection and diagnosis of PCP infections
(10,11). Besides the standard procedures of
bronchoalveolar lavage (BAL) and induced spu-
tum (IS) sampling, recent studies indicate that it
i sp o s s i b l et oa m p l i f yP.carinii DNA sequences by
polymerase chain reaction (PCR) directly from
blood or serum samples and from nasopharyngeal
aspirates of PCP patients (11,12).Further studies
areneededtoconfirmthataPCR-baseddiagnostic
tool superior to microscopy can be adapted for use
in clinical settings. A serologic tool that will dis-
tinguish recent PCP infections from those past is
also needed.
Prophylaxis failures have been reported for
both trimethoprim-sulfamethoxazole(TMP-SMX)
and pentamidine (13-16). Studies evaluating
these cases, however, are frequently complicated
by the difficulties in assessing and confirming
patient compliance with the prophylaxis regimen.
The only factor that has a significant correlation
withfailureinmostcases,however,isthepatient’s
CD4+ T lymphocyte count (14). Although this cor-
relation would be expected because of the general
increased risk for PCP associated with CD4+ cell
depletion (6) and the increase in prophylaxis com-
plications in HIV-infected patients (17), these
drugs may not eliminate all organisms, and some
degree of patient immunity may be required to
clear or control the infection. What role, if any,
specificantimicrobialresistancemechanismsplay
in the reported treatment failures has not been
shown; however, the emergence of resistance is
always a threat. Likewise, long-term TMP-SMX
prophylaxis increases the possibility for the selec-
tion of antimicrobialresistance in bacterialpatho-
g e n s ,s o m eo fw h i c ha r ei m p o r t a n tp o t e n t i a l
causesofpneumoniainHIV-infectedpatients(18).
Identifying potential antimicrobial resistance
mechanisms in P. carinii is difficult because of the
lack of an established culture system for human
P. carinii that would allow traditional antimicro-
bial sensitivity testing.
At least three separate lines of data suggest
that P. carinii is a commonly encountered organ-
ism: the high seroprevalence rates reported in
normal populations (19), the rapid rate at which
infants acquire primary infections (8) and AIDS
patients become reinfected after successful treat-
ment (20), and the amplification of P. carinii-spe-
cific DNA from ambient air sampled from the
environment (e.g.,an apple orchard)(21) andfrom
rooms of animals and patients with PCP (22).
Airborne transmission has been demonstrated for
PCP in rats (23-26) and is by far the most likely
mechanism proposed for natural exposure to P.
carinii in humans (2,22). Given the similarities
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the enigma surrounding the issue of environ-
mentalsources forP.carinii,ithas been suggested
that P. carinii may in fact be a dimorphic fungus,
ubiquitous in the environment and disseminated
by airborne spores (27). Identifying the specific
environmental source or sources of P. carinii is
critical to understanding the epidemiology of PCP
and establishing guidelines for preventing its
transmission.
It is generally accepted that P. carinii strains
from rats do not infect humans and that human
strains do not infect rats;however,we do not know
the host boundaries for a given P. carinii strain or
if all isolates from a given host display the same
degreeofhostrestrictions(28,29).Infact,acareful
evaluation of the available data concerning P.
carinii of numerous hosts suggests that P. carinii
may represent a collection of diverse fungal spe-
cies (30). Like drug resistance research, studies
aimed at strain/species characterization are gen-
erally hindered by the difficulties in culturing
human P.carinii and the lack of refined molecular




Oneof the essentialreasons forcultivatingany
particularpathogenisforstrainidentificationand
characterization that would elucidate such spe-
cific phenotypic characteristics as virulence fac-
tors, antimicrobial sensitivity levels, and factors
associatedwithtransmissibility.Theisolationand
cultivation of individual strains,and ultimately of
clones, would provide a homogeneous population
of organisms from which the desired information
can be obtained and a pure source of genetic ma-
terial for constructing DNA libraries and identify-
ing relevant genes.
Intheabsenceofcultivation,investigatorshave
been able to begin addressing some of the basic
epidemiologically important issues by applying
PCR-based technology. In these studies, the DNA
sequence of specific genetic loci from P. carinii is
usually amplified from BAL,IS,or serum samples
from PCP patients, using highly specific oligonu-
cleotide primers. Inherent problems exist in this
approach (which are discussed below); however,
the approach has allowed the identification of
genotypic differences in P. carinii populations
sampled from the lungs of different patients and
even from the lungs of the same patient during
different PCP episodes. Great potential exists in
applyingthistechnologytodevelopmolecularpro-
files of P. carinii isolates that could ultimately
allow the particular genotypes to be linked to
specific epidemiologically relevant phenotypes.
MolecularTyping
Five to ten different genetic loci have been
identified as potentially informativefor molecular
characterization and typing (30-33). Concerning
the typing that has actually been performed on
human samples, the primary loci evaluated in-
clude:1)a346-bpregionofthemitochondriallarge
s u b u n i tr R N Ag e n e( mt lsrRNA) (10) and 2) a
550-bpfragmentcontainingthenuclearribosomal
internal transcribed spacer regions 1 and 2 (ITS1
and ITS2) (34). When these loci are considered
collectively,nucleotidevariationcanbedetectedat
approximately 37 different positions. Work is in
progress in several laboratories, both to type pa-
tient isolates according to the available loci and to
identify additional genetic loci to more thoroughly
define a given genotype.
The primary obstacles to the development of a
molecular typing scheme based on PCR-amplified
DNA sequence data obtained from PCP patients
include the following: 1) multiple strains may in-
fect a single patient at a given time; 2) a diploid
organism of a single strain may be heterozygous
with respect to a particular polymorphic locus; 3)
presumed single genes could have multiple copies
in a single genome, which could give the appear-
ance of genetic polymorphism; 4) amplified DNA
sequence data might be confounded because of
other fungal agents such as Cryptococcus or Can-
dida; and 5) inferences that can be drawn from
restricted sequence data (i.e., gene typing versus
strain typing) are limited. Although these prob-
lems are not insurmountable, they must be con-
sidered when evaluating data obtained by this




1. Recent advances in molecular-based typing
should be combined with epidemiologic studies to
investigate the transmission of P. carinii and new
strategies for control.
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fied for use in typing, along with the genetic loci
that are available. These new loci must be shown
to represent single-copy genes. Also, new molecu-
lar approaches should be developed that will in-
crease the current capacity to resolve genotypic
variation among P. carinii strains.
3. Genetic variation should be investigated
among P. carinii strains that could be linked to
variations in factors such asstrainvirulence,drug
resistance, or transmissibility.
4.The critical issue regarding person-to-person
transmission is not so much whether it occurs, as
whether it contributes to infection significantly
more than airborne sources in the environment.
Thus, it must be determined whether there is any
benefit to establishing complex protocols that en-
sure that patients are carefully protected from
each other if they can become infected from other
sources in the environment. Consequently, the
importance of person-to-person transmission in
the epidemiology of PCP should be defined.
5. The role of latent P. carinii infection as a
source of PCP in immunocompromised persons
should be clarified.
Diagnosis,Treatment,andPrevention
1. New tools for noninvasive early diagnosis of
PCP, including culture systems, molecular ap-
proaches, and serologic tests that can distinguish
recent and past PCP infections are needed.
2. In the United States, clinician compliance
with recently published U.S. Public Health Serv-
ice/Infectious Diseases Society of America guide-
lines on the treatment and prophylaxis of PCP
should be evaluated.
3. Studies should be initiated to develop addi-
tional drugs for PCP treatment and prophylaxis.
4. New approaches for improving patient com-
pliance with prescribed PCP prophylaxis must be
devised and evaluated.
5.Methodsfordetectingthepossibleemergence
of drug resistance to P. carinii should be stand-
ardized.
6. Standard decontamination procedures for
respiratory therapy equipment and pulmonary
diagnostic instruments should be evaluated to
confirm that they effectively eliminate all viable
P. carinii.
Environmental Reservoirs and General Biology
1. Environmental sources and the coinciding
infective stage(s) of P. carinii should be detected
and evaluated.
2. The host range of P. carinii from various
sources (i.e., to what degree are humans suscepti-
ble to P. carinii from nonhuman sources?) should
be determined.
Acknowledgments
We thank the following colleagues for their contribu-
tions: C. William Angus, Marilyn S. Bartlett, Jeanne M.
Bertolli, Suzanne Binder, Daniel G. Colley, Frank H. Col-
lins, Melanie T. Cushion, Alexandre J. DaSilva, Jeffrey S.
Duchin,BrianR.Edlin,WalterT.Hughes,JohnA.Jernigan,
Dennis D. Juranek, Jonathan R. Kaplan, Scott P. Keely,
Chao-Hung Lee, Joseph E. McDade, Stephen A. Moser,
Norman J. Pieniazek, Frank F. Richards, James W. Smith,
Eleanor K. Spicer, James R. Stringer, and Craig M. Wilson.
Mary E. Bartlett provided editorial assistance.
Charles B. Beard, Ph.D., and Thomas R. Navin, M.D.
Centers for Disease Control and Prevention
Atlanta, Georgia, USA
References
1. Walzer PD, editor. Pneumocystis carinii pneumonia.
New York: Marcel Dekker, 1994.
2. Cushion MT. Transmission and epidemiology. In:
Walzer PD, editor. Pneumocystis carinii pneumonia.
New York: Marcel Dekker, 1994:123-40.
3. Chen W, Gigliotti F, Harmsen AG. Latency is not an
inevitable outcome of infection with Pneumocystis
carinii. Infect Immun 1993;61:5406-9.
4. Vargas SL,Hughes WT,Wakefield AE,Oz HS.Limited
persistence in and subsequent elimination ofPneumo-
cystiscariniifromthelungsafterP.cariniipneumonia.
J Infect Dis 1995;172:506-10.
5. Keely SP, Stringer JR, Baughman RP, Linka MJ,
Walzer PD, Smulian AG. Genetic variation among
Pneumocystis carinii hominis isolates in recurrent
pneumocystosis. J Infect Dis 1995;172:595-8.
6. Phair J,Muñoz A,Detels R,Kaslow R,Rinaldo C,Saah
A.The risk of Pneumocystis carinii pneumonia among
men infected with human immunodeficiency virus
type 1. N Engl J Med 1990;322:161-5.
7. Hughes WT,Price RA,Havron SF,Sisko F,Havron SF,
Kafatos AG, Schonland M, et al. Protein-calorie mal-
nutrition:a host determinant forPneumocystis carinii
infection. Am J Dis Child 1974;128:44-52.
8. Hughes WT.1994.Clinical manifestations in children.
In:WalzerPD,editor.Pneumocystiscariniipneumonia.
New York: Marcel Dekker, 1994:319-29.
9. Simonds RJ, Lindegren ML, Thomas P, Hanson D,
Caldwell B, Scott G, et al. Prophylaxis against Pneu-
mocystis carinii pneumonia among children with per-
inatally acquired human immunodeficiency virus
infection in the United States. N Engl J Med
1995;332:786-90.
Commentary
Vol. 2, No. 2 —April-June 1996 149 Emerging Infectious Diseases10. Wakefield AE, Pixley FJ, Banerji S, Sinclair K, Miller
RF,Moxon ER,et al.Detection of Pneumocystis carinii
with DNA amplification. Lancet 1990; 336:451-3.
11. Atzori C, Lu J-J, Jiang B, Bartlett MS, Orlando G,
Queener SF, Smith JW, et al. Diagnosis of Pneumocys-
tis carinii pneumonia in AIDS patients by using po-
lymerase chain reactions on serum specimens.J Infect
Dis 1995;172:1623-6.
12. Richards CGM, Wakefield AE, Mitchell CD. Detection
of pneumocystis DNA in nasopharyngeal aspirates of
leukaemic infants with pneumonia. Arch Dis Child
1994;71:254-5.
13. Montgomery AB, Feigal DW, Sattler F. Pentamidine
aerosol versus trimethoprim-sulfamethoxazole for
Pneumocystis carinii in acquired immune deficiency
syndrome.Am J Respir Crit Care Med 1995;151:1068-
74.
14. Saah AJ, Hoover DR, Peng Y, Phair JP, Visscher B,
Kingsley LA,et al.PredictorsforfailureofPneumocys-
tis carinii pneumonia prophylaxis. JAMA
1995;273:1197-1202.
15. Lecuit M, Livartowski J, Vons C, Goujard C, Lamaigre
G, Delfraissy J-F, et al. Resistance to trimethoprim-
sulfamethoxazoleandsensitivitytopentamidinether-
apy in an AIDS patient with hepatosplenic
pneumocystosis. AIDS 1994;8:1506-7.
16. Torres RA, Barr M, Thorn M, Gregory G, Keily S,
Chanin E, et al. Randomized trial of dapsone and
aerosolized pentamidine for the prophylaxis of Pneu-
mocystis carinii pneumonia and toxoplasmic encepha-
litis. Am J Med 1993;95:573-83.
17. WalkerRE,MasurH.Currentregimensoftherapyand
prophylaxis. In: Walzer PD, editor. Pneumocystis
carinii pneumonia. New York: Marcel Dekker,
1994:439-66.
18. Schwartz RH, Khan WN, Akram S. Penicillin and
trimethoprim-sulfamethoxazole-resistant pneumo-
cocci isolated from blood cultures of three infants in
metropolitan Washington, DC: a harbinger of serious
future problems? Pediatr Infect Dis J 1991;10:782-3.
19. Smulian AG, Walzer PD. Serological studies of Pneu-





New York: Marcel Dekker, 1994:331-59.
21. Wakefield AE. Detection of DNA sequences identical
to Pneumocystis carinii in samples of ambient air. J
Euk Microbiol 1994;41:116S.
22. Bartlett MS, Lee C-H, Lu J-J, Bauer NL, Betts JF,
McLaughlin GL, et al. Pneumocystis carinii detected
in air. J Euk Microbiol 1994;41:75S.
23. Hendley JO, Weller TH. Activation and transmission
in rats of infection with Pneumocystis.P r o cS o cE x p
Biol Med 1971;137:1401-4.
24. Walzer PD, Schnelle V, Armstrong D, Rosen PP. Nude
mouse: a new experimental model for Pneumocystis
carinii infection. Science 1977;197:177-9.
25. Hughes WT, Bartley DL, Smith BM. A natural source
of infection due to Pneumocystis carinii. J Infect Dis
1983; 147:595.
26. Hughes WT. Natural habitat and mode of transmis-
sion.In:Pneumocystis carinii pneumonitis, vol I.Boca
Raton, FL: CRC Press, 1987:97-105.
27. Dei-casE,CailliezJC,PalluaultF,AliouatEM,Mazars
E, Soulez B, et al. Is Pneumocystis carinii ad e e p
mycosis-like agent? Eur J Epidemiol 1992; 8:460-70.
28. Smith JW, Bartlett MS. Laboratory diagnosis of pneu-
mocystosis. Clin Lab Med 1991;11:957-75.
29. Armstrong MYK,Cushion MT.In vitro cultivation.In:
Walzer PD, editor. Pneumocystis carinii pneumonia.
New York: Marcel Dekker, 1994:3-24.
30. Stringer JR. The identity of Pneumocystis carinii:n o t
a single protozoan, but a diverse group of exotic fungi.
Infect Agents Dis 1993;2:109-17.
31. Edman JC, Sogin ML. Molecular phylogeny of Pneu-
mocystis carinii. In: Walzer PD, editor, Pneumocystis
carinii Pneumonia. New York: Marcel Dekker, Inc.,
1994:91-105.
32. The Pneumocystis Workshop. Revised nomenclature
for Pneumocystis carinii. J Euk Microbiol
1994;41:121S-22S.
33. Lu J-J, Chen C-H, Bartlett MS, Smith JW, Lee C-H.
ComparisonofsixdifferentPCR methodsfordetection
of Pneumocystis carinii. J Clin Microbiol
1995;33:2785-8.
34. LuJ-J,BartlettMS,ShawMM,QueenerSF,SmithJW,
Ortiz-Rivera M, et al. Typing of Pneumocystis carinii
strains that infect humans based on nucleotide se-
quence variations of internal transcribed spacers of
rRNA genes. J Clin Microbiol 1994;32:2904-12.
Commentary
Emerging Infectious Diseases 150 Vol. 2, No. 2 —April-June 1996